Analysis of Market Access Agreements in Turkey

BACKGROUND: Reimbursement agencies are increasingly adopting innovative reimbursement approaches for new and expensive technologies. Social Security Institution (SSI), Turkey`s reimbursement agency, established the Alternative Reimbursement Commission (ARC) on February 10, 2016. This study aimed to understand the implementations of market access agreements in recent years in Turkey.METHODS: Decisions of the Health Services Pricing Commission published in the official gazette , and information from the Turkey Pharmaceuticals and Medical Devices Agency, the Abroad Drug List, Health Implementation Communique published by SSI with additional lists, such as the Annex-4A List of Reimbursed Medicines and the Annex-4C Abroad Drug Price List, were used. The data was transferred to Windows Office Excel files, and a descriptive analysis was conducted and evaluated by two market access experts.RESULTS: There were 57 drugs included in the coverage of reimbursement with alternative reimbursement since the application was started in Turkey. 35 of them were added to Annex-4A and 22 of them to Annex-4C. Furthermore, 45.6% of the drugs had an Anatomic Therapeutic Chemical Classification (ATC) code of l-antineoplastic and immunomodulating agents, 28% were orphan drugs, 44 of them had a confidential discount rate, and financial-based agreement models were preferred for nearly all agreements.CONCLUSIONS: Turkey has been implementing market access agreements since mid-2016. In the past 3 years, 57 drugs have been covered for reimbursement under the new implementation. Further analysis should be conducted to understand the decision-making process involved

Cost-Effectiveness Analysis of the Triclip (TM) Transcatheter Tricuspid Valve Repair System in Patients with Tricuspid Regurgitation

Background: Tricuspid regurgitation is o condition that affects 1.6 million patients in the United States and is independently associated with morbidity and mortality. The TriClip (TM) procedure repairs the tricuspid valve without the need for open-heart surgery. The aim of this study is to evaluate the cost-effectiveness of TriClip (TM) treatment in patients with advanced tricuspid regurgitation from the Turkish reimbursement agency perspective

Determining the impact of vitamin C use with the common cold on loss of labour and medical treatment costs for Turkey

Objectives As one of the most common health problems, the common cold may lead to negative consequences such as work or school absenteeism, poor productivity and labour loss. Vitamin C supports immune system defences by supporting the various cellular functions of the immune system, both congenital and adaptive. The purpose of this study is to evaluate the use of vitamin C in white-collar workers and its impact on medical care costs and its impact on the workforce in association with the common cold